Entos Pharmaceuticals Receives Approval from Health Canada to Begin Clinical Trial for COVID-19 Vaccine Booster

EDMONTON, Alberta & SAN DIEGO–(BUSINESS WIRE)–Entos Pharmaceuticals (Entos or the Company), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix PLV nucleic acid delivery platform, and its partner, Aegis Life, Inc. (Aegis), today announced that Entos has received approval from Health Canada to initiate a phase 1/2 clinical trial (NCT06436911) evaluating Covigenix VAX-002, an investigational COVID-19 booster vaccine. Formulated using the Entos Fuso
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks